Ladies and Gentlemen:

These are very exciting times for the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), the Georgia Department of Human Resources Division of Mental Health Developmental Disabilities and Addictive Diseases (DHRMHDDAD) and the Opioid Treatment Providers of Georgia (OTPG). As we convene this vital conference for the first time in the State of Georgia, more specifically, the city of Atlanta, my Georgia colleagues and I are proud and honored to serve as your host.

On behalf of AATOD, DHRMHDDAD, and OTPG, I invite each of you to a stimulating and enlightening series of workshops and plenary sessions that are sure to expand your knowledge and clinical practice of opioid treatment. The theme for this year’s conference, “TREATING PEOPLE WITH DIGNITY: Working with Criminal Justice and Health Care Systems” is most befitting the process of addiction recovery and reflects the efforts of all providers nationally and abroad.

Drawing upon previous conference evaluations, our conference planning committee has worked diligently to assemble an enhanced program that highlights numerous workshops, exhibits, hospitality activities and entertainment as well as local facility tours. As always, Saturday and Sunday will feature a series of cutting edge pre-conference sessions for veteran clinicians, clinicians new to the field and all other conference participants.

In addition to workshops, plenary sessions, facility tours and the free-time attractions of Atlanta, there will be a Welcome Reception for all conference participants that will feature southern cuisine and live entertainment. As always, a special focus of this year’s conference will be the Awards Banquet. This is the setting where the esteemed Nyswander/Dole “Marie” Award is presented to individuals who have been nominated and selected by fellow treatment professionals in honor of their significant contributions to the opioid treatment profession, in addition to the Association’s “Friend of the Field” Award.

Finally, we have amassed a huge contingent of volunteers who are genuinely committed to ensuring your conference experience will be well above all expectations. Our volunteers are well prepared and ready to assist by extending to you what we refer to as world class “southern hospitality.”

It is a pleasure to serve as the 2006 Conference Chair. Therefore, on behalf of the AATOD Conference Planning Committee, thank you for your continued support. I look forward to seeing you in Atlanta.

Sincerely yours,

Terry L. Willis, MS
2006 Conference Chair
<table>
<thead>
<tr>
<th>DAY</th>
<th>DATE</th>
<th>TIME</th>
<th>EVENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SATURDAY</strong></td>
<td><strong>APRIL 22</strong></td>
<td></td>
<td><strong>Day 1</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:00 PM</td>
<td>The Certified Methadone Advocate (CMA) Training Course</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Buprenorphine, OTP &amp; Office-Based Treatment of Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 5:00 PM</td>
<td>Operationalizing Cultural Competence in Behavioral Health Services</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Opioid Treatment Program Accreditation – Town Hall Meeting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 8:00 PM</td>
<td>American Association for the Treatment of Opioid Dependence, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Open Board Meeting</td>
</tr>
<tr>
<td><strong>SUNDAY</strong></td>
<td><strong>APRIL 23</strong></td>
<td></td>
<td><strong>Day 2</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 7:30 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 12:30 PM</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 5:00 PM</td>
<td>NIDA Clinical Trials Network</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>Best Practices From Treatment Improvement Protocol 43</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 5:30 PM</td>
<td>State Methadone Authorities’ Meeting (Closed Session for State and Federal Officials)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 4:00 PM</td>
<td>Hepatitis Education for Opioid Treatment Providers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 4:00 PM</td>
<td>Risk Management in the OTP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>European Opiate Addiction Treatment Association (EUROPAD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:00 PM – 5:00 PM</td>
<td>Exhibit Hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30 PM – 7:30 PM</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meetings (Open)</td>
</tr>
<tr>
<td><strong>MONDAY</strong></td>
<td><strong>APRIL 24</strong></td>
<td></td>
<td><strong>Day 3</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 7:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 12:00 PM</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 7:00 PM</td>
<td>Posters in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Opening Plenary Session – Overview of National Policy Initiatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions / Hot Topic Round Tables</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 3:30 PM</td>
<td>Refreshment Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 7:00 PM</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:30 PM – 5:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 7:00 PM</td>
<td>Networking Reception in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 8:30 PM</td>
<td>Methadone Anonymous Meetings (Open)</td>
</tr>
<tr>
<td><strong>TUESDAY</strong></td>
<td><strong>APRIL 25</strong></td>
<td></td>
<td><strong>Day 4</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 12:30 PM</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 4:30 PM</td>
<td>Posters in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Middle Plenary Session – Medication Assisted Treatment &amp; The Criminal Justice System</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 4:00 PM</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 3:30 PM</td>
<td>Refreshment Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 4:30 PM</td>
<td>Poster Author Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 9:30 PM</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 PM – 10:30 PM</td>
<td>Methadone Anonymous Meetings (Open)</td>
</tr>
<tr>
<td><strong>WEDNESDAY</strong></td>
<td><strong>APRIL 26</strong></td>
<td></td>
<td><strong>Day 5</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 1:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 8:00 AM</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 9:30 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:45 AM – 11:15 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30 AM – 12:45 PM</td>
<td>Closing Plenary Session – Spiritual &amp; Political View of Chronic Addiction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 3:30 PM</td>
<td>Clinic Tours</td>
</tr>
</tbody>
</table>
Pre-Conference Sessions

Saturday, April 22, 2006

➤ THE CERTIFIED METHADONE ADVOCATE (CMA) TRAINING COURSE

Additional Fees Apply – See Below for Registration Information

TIME: 8:00 AM – 9:00 AM (Pre-Registration)
9:00 AM – 5:00 PM (Training Course)

<table>
<thead>
<tr>
<th>Frederick W. Christie, MA</th>
<th>Ray Caesar</th>
<th>Thomas Kresina, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFIRM</td>
<td>OKDMHAS/SMA</td>
<td>NIDA/CSAT</td>
</tr>
<tr>
<td>Long Island, NY</td>
<td>Oklahoma City, OK</td>
<td>Rockville, MD</td>
</tr>
<tr>
<td>Rebecca Brooks, CMA</td>
<td>Herman Joseph, PhD</td>
<td>J. Thomas Payte, MD</td>
</tr>
<tr>
<td>NAMA/LHRC</td>
<td>NAMA</td>
<td>Colonial Management Group</td>
</tr>
<tr>
<td>Ontario, Canada</td>
<td>New York, NY</td>
<td>Orlando, FL</td>
</tr>
<tr>
<td>Sharon Dembinski, MS</td>
<td>Joycelyn Woods, MA</td>
<td>Legal Action Center</td>
</tr>
<tr>
<td>NAMA</td>
<td>NAMA/Faces &amp; Voices of Recovery</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Webster, MA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

It is the view of the National Alliance of Methadone Advocates (NAMA) that everyone who supports the use of methadone treatment is a potential methadone advocate. We encourage all supporters of methadone treatment, patient and non-patient, to become Certified Methadone Advocates (CMA) so that all energies directed toward the advancement of methadone treatment produce positive results.

This course fulfills the training requirement for Certification as a Methadone Advocate. This course involves 8 hours of rigorous training.

With these goals in mind the course presentation is constituted as follows:

- **Addiction and Methadone** – scientifically accurate yet in language understandable to the non-clinician.
- **Regulations and Accreditation** – explained by experts from CSAT who understand the systemic complexity of ODT. Advocacy through collaboration specifically State Methadone Authority contact.
- **Methadone Mythology** – exposing of the myths surrounding methadone treatment.
- **The Certified Methadone Advocate (CMA)** – the mechanism of certification and how it will professionalize those committed to advocacy. Including advocacy on the Net and Methadone Anonymous.
- **Methadone Stigma** – a history of administrative and community prejudice directed at methadone patients, plus analyses of possible solutions.
- **Methadone Treatment & Pregnancy** – Understanding the issues, specific implications and methods of treatment for pregnant women undergoing ODT, advocating in a legal setting, advocating in a health services community, advocating for the newborn in a health treatment facility setting.
- **Hepatitis C & HIV/AIDS** – Addressing this aspect of healthcare, vital information for all opiate addicted individuals, including but not limited to treatment, legal, social and confidentiality issues.

Candidates for certification must register with NAMA prior to the conference. Registration information available at: www.methadone.org/registration.doc

There is a separate registration fee of $100.00 for this pre-conference event. The fee includes all materials, 2006 membership in NAMA, and the application for CMA. The training will adjourn between 12:00 PM and 1:00 PM. Lunch is not provided by NAMA, however, a listing of reasonable locations for lunch will be provided.

Sponsored by the National Alliance of Methadone Advocates (NAMA).
Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment and Mallinckrodt, Inc.
BUPRENORPHINE, OTP AND OFFICE – BASED TREATMENT OF OPIOID DEPENDENCE

Additional Fees Apply – See Below for Registration Information

TIME: 8:00 AM – 5:30 PM

Course Director: David Fiellin, MD, Yale University School of Medicine, New Haven, CT
Course Faculty:
- Leslie Amass, PhD, Friends Research Institute, Inc., Los Angeles, CA
- Ira Marion, MA, Division of Substance Abuse, Albert Einstein College of Medicine, New York, NY
- Judith Martin, MD, 14th Street Clinic, Oakland, CA
- Lynn Sullivan, MD, Yale University School of Medicine, New Haven, CT

The Drug Addiction Treatment Act of 2000 (PL106-310, Section 3502) permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV, or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine sublingual and the combination of buprenorphine/naloxone are approved by FDA for use in detoxification and maintenance treatment of opioid dependence. Physicians are qualified if they are certified in Addiction Medicine or Addiction Psychiatry.

EDUCATIONAL OBJECTIVES:

After participating in this course, you should be able to describe:

- The prerequisites for a physician to begin prescribing buprenorphine in office-based practice
- The clinically relevant pharmacological characteristics of buprenorphine
- Factors to consider in determining if a patient is an appropriate candidate for office-based treatment
- Induction, maintenance, and detoxification protocols

- Strategies for integrating psychosocial care with office-based pharmacological treatment
- Treatment strategies for management of chronic and acute pain in patients in maintenance treatment for opioid dependence
- The appropriate monitoring of patients with HIV and/or HCV who are receiving buprenorphine

PROGRAM TOPICS AND TIME

7:00 AM – 8:00 AM Registration and Mandatory Sign-In

8:00 AM – 5:30 PM Program, Including Lunch

- Overview of Opioid Dependence
- Rationale for Opioid Agonist Treatment
- Legislative Changes Allowing Office-Based Treatment of Opioid Dependence, Including the Drug Addiction Treatment Act of 2000
- General Opioid Pharmacology
- Pharmacology of Buprenorphine and Buprenorphine/Naloxone
- Efficacy and Safety of Buprenorphine/Naloxone
- Clinical Use of Buprenorphine and Buprenorphine/Naloxone, Including Induction, Maintenance, and Pharmacologic Withdrawal
- Patient Assessment and Selection
- Office Procedures and Logistics
- Psychiatric Co-Morbidity in Opioid Dependent Patients
- Medical Co-Morbidity in Opioid Dependent Patients
- The Role of Psychosocial Counseling in the Treatment of Opioid Dependence
- Special Treatment Populations, Including the Management of Patients who Develop Pain while Receiving Buprenorphine/Naloxone, Pregnancy and Adolescents

5:30 PM Mandatory Sign-Out

As part of the requirements to obtain the waiver, physicians not otherwise qualified must complete not less than 8 hours of training. Physicians who complete this 8-hour course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of HHS along with the request for the waiver. If you give ASAM permission to do so, ASAM will report your name directly to the Secretary of HHS within 4 weeks of the program, if you have attended the full 8 hours, eliminating the need for you to send the certificate of attendance. Because ASAM will be called upon to confirm that participants have attended a full 8 hours, you must bring a photo identification to show as part of the sign-in process; you must confirm your attendance with your signature at the beginning of both the morning and the afternoon sessions; and you must sign out at the conclusion of the program.

There is a separate registration fee for this pre-conference event. Space is limited and pre-registration is required. To register for this pre-conference, call 888-362-6784 or register on the web at www.DOCCPTIN.com. Registration fees: $125 for non-ASAM physicians; $100 for ASAM members; $75 for non-physicians; $0 for residents.

Sponsored by the American Society of Addiction Medicine.
Supported by an unrestricted continuing medical educational grant provided by Reckitt Benckiser.
Pre-Conference Sessions

Saturday, April 22, 2006

➤ OPERATIONALIZING CULTURAL COMPETENCE IN BEHAVIORAL HEALTH SERVICES

TIME: 8:30 AM – 5:00 PM

Maxine Fuller, MS  Robert Johnson, MEd
McKinley Group, Inc.  Accreditation NOW
Atlanta, GA  Columbia, MO

Generally, behavioral health professionals agree that cultural competence is a critical factor in providing quality service to ethnically, racially, and culturally diverse patient populations. Providers also know that awareness of diverse groups alone will not facilitate the effective delivery of behavioral health services.

The goal of this one-day workshop is to create an understanding of the impact of cultural competence in effective service delivery, to develop strategic approaches that address diversity throughout the provision of care, and to begin implementing the National Standards for Cultural Competence in Healthcare.

Upon completion of this workshop, participants will be able to:
• Develop a framework for discussing and learning about cultural competence
• Discuss the business case for providing culturally competence services
• Address barriers to becoming more culturally competent within service provision
• Use the National Standards for Cultural Competence in Healthcare to assess an organization’s capacity to serve racially and culturally diverse patients
• Discuss tools, strategies, and structures to operationalize cultural competence in behavioral health services
• Draft a strategic plan for diversity and cultural competence that involves all levels of the organization

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

➤ OPIOID TREATMENT PROGRAM ACCREDITATION – TOWN HALL MEETING

TIME: 1:00 PM – 5:00 PM

Megan Marx, MPA  Mary Cesare-Murphy, PhD
Joint Commission on Accreditation of Healthcare Organizations  Joint Commission on Accreditation of Healthcare Organizations
Littleton, CO  Oakbrook Terrace, IL

This pre-conference session is designed to be an open forum for Joint Commission accredited opioid treatment programs to discuss accreditation questions, concerns and challenges. The presenters will provide an overview of OTP accreditation to date and will then open up the floor for participant’s questions.

Topics expected to be reviewed/discussed include:
• Changes in the accreditation process as a result of “Shared Visions – New Pathways”
• Use of the Periodic Performance Review (PPR) as a continuous accreditation readiness tool
• National Patient Safety Goals 2006
• OTP accreditation training opportunities

At the end of this presentation participants will:
• Be able to identify commons areas of concern amongst Joint Commission accredited OTPs.
• Be able to identify Joint Commission resources available to assist OTPs in the accreditation process.
• Have the opportunity to network and strategize with Joint Commission staff and other Joint Commission accredited OTPs with regard to the ongoing process of accreditation readiness.

Registration for this workshop is open to all Joint Commission accredited Opioid Treatment Programs. To pre-register for this workshop please contact Megan Marx at mmarx@jcaho.org or 720-348-0672.

Sponsored by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO).
Pre-Conference Sessions

Sunday, April 23, 2006

➤ OPIOID MAINTENANCE PHARMACOTHERAPY: A COURSE FOR CLINICIANS

Additional Fees Apply – Please refer to registration form

TIME: 8:00 AM – 5:30 PM

Laura McNicholas, MD  
VA Medical Center  
Philadelphia, PA

J. Thomas Payte, MD  
Colonial Management Group  
Orlando, FL

Susan Neshin, MD  
JSAS Healthcare, Inc.  
Asbury Park, NJ

Trusandra Taylor, MD  
NETSTEPS  
Philadelphia, PA

This course will serve as a primer for clinicians working in methadone treatment programs. Physicians, physician’s assistants, nurses, and other interested personnel who want to learn about opioid treatment practices are encouraged to attend. Overall the course presents state of the art educational information for opioid addiction treatment.

The updated and expanded curriculum will include epidemiology, opioid pharmacology/neurobiology, evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug to drug interactions, adverse effects, methadone deaths, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, and an overview of buprenorphine. Participants will receive a comprehensive syllabus with reference and resource materials.

Four experienced opioid treatment medical directors will present, in lecture and question/answer format, focusing on information essential for the clinician to function in an opioid treatment program. To integrate the learning objectives, participants are encouraged to discuss challenging problems and clinical issues during question and answer segments that will facilitate the didactic principles.

The $150.00 registration fee includes a morning coffee service, afternoon luncheon, and the evening’s Welcome Reception.

Sponsored by the American Association for the Treatment of Opioid Dependence in cooperation with the American Academy of Addiction Psychiatry and the American Osteopathic Academy of Addiction Medicine.

Supported by the National Institute on Drug Abuse.

➤ COUNTERING OPIOID STIGMA: COMMUNICATING MESSAGES TO INFLUENCE PUBLIC PERCEPTION

TIME: 8:30 AM – 12:30 PM

Frank Carillo, MBA  
Executive Communications Group  
Englewood, NJ

Colleen O’Connor, MS  
Executive Communications Group  
Englewood, NJ

Opioid treatment programs and patients have historically been the target of negative public opinion and adverse media coverage. This has affected our ability to influence national drug policy, explain the science of opioid addiction and treatment, gain the funding necessary to provide quality treatment to all who require it, and ultimately to operate in the best interests of our patients and communities.

This presentation will roll-out 3 key messages specifically designed to counter the stigma and stereotypes deeply embedded in the perception of opioid addiction and medication-assisted treatment. These messages resulted from a year-long pilot project entitled “Communicating Messages That Achieve Results”. Providers will hear these messages for the first time and learn how to communicate them in order to create a positive impact within their communities. The workshop will include Q&A techniques designed to deal with emotional audiences while reinforcing the presenter’s objective.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.
Supported by VistaPharm, Inc.
Pre-Conference Sessions

Sunday, April 23, 2006

➤ THE NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK (CTN)
“Treating People with Dignity and Evidence Based Medicine: Emerging Research Findings on Buprenorphine, Hepatitis C and Prescription Drug Addiction”

TIME: 8:30 AM – 5:00 PM
8:30 AM – 8:45 AM     Registration and Continental Breakfast
Session Chair: Betty Tai, PhD, Center for the Clinical Trials Network, National Institute on Drug Abuse, NIH, Bethesda, MD

The Clinical Trials Network (CTN) is an important program of the National Institute on Drug Abuse (NIDA) focused on the design and implementation of clinically relevant studies in the field of drug addiction treatment research. It consists of 17 geographically diverse “Nodes” centered in key academic institutions, partnering with local Community Treatment Programs (CTPs).

The objectives of the pre-conference session are:
1. Participants will learn how to use Buprenorphine in clinical settings including rapid detoxification, stabilization, and tapering from opioid addiction.
2. Participants will learn about the nature and extent of the problem of infectious diseases, especially Hepatitis C, and will learn innovative treatment approaches now being used in community treatment programs.
3. Participants will learn about using Buprenorphine and individual drug counseling to treat prescription opioid addicts including those with chronic pain.
4. Participants will learn about the availability of prescription drugs over the internet.

AGENDA

8:45 AM     Welcome & Introduction
Betty Tai, PhD
Director, Center for the Clinical Trials Network
National Institute on Drug Abuse, NIH
Bethesda, MD

Buprenorphine: Pharmacotherapy for Addiction

9:00 AM     Buprenorphine Opioid Detoxification Study Results: Treatment and Policy Implications
Walter Ling, MD
Principal Investigator, Pacific Region Node, NIDA CTN
Director, Integrated Substance Abuse Programs, Los Angeles, CA
Professor of Psychiatry and Biobehavioral Sciences, UCLA
Los Angeles, CA

9:40 AM     Buprenorphine Treatment in Pregnant Women
Hendree Jones, PhD
Associate Professor, Department of Psychiatry, JHU
Research Director, Center for Addiction & Pregnancy
Baltimore, MD

10:20 AM     Dissemination: Buprenorphine Awareness Package
Thomas Freese, PhD
Director, Pacific Southwest Addiction Technology Transfer Center (ATTC)
Los Angeles, CA

11:00 AM     Buprenorphine in the Community Setting
Allan J. Cohen, MA
Director of Research and Training
Bay Area Addiction Research and Treatment, Inc.
Los Angeles, CA

11:30 AM     Lunch
Infectious Diseases: HCV Comorbidity

12:30 PM  **HCV Infection: A Scientific View**  
David Thomas, MD  
Associate Professor, Division of Infectious Diseases  
Johns Hopkins University School of Medicine  
Baltimore, MD

1:10 PM  **Policies: HCV Services in Substance Abuse Treatment**  
Lawrence Brown, MD  
Senior Vice President, Addiction Research & Treatment Corporation  
Clinical Associate Professor of Public Health, Weill Medical College, Cornell University  
Immediate Past President, American Society of Addiction Medicine  
Brooklyn, NY

1:50 PM  **HCV Education: Improving Treatment**  
Diana Sylvestre, MD  
Assistant Clinical Professor, Department of Medicine, University of California-San Francisco  
Oakland, CA

2:30 PM  **The Community Perspective**  
Paul McLaughlin, MA  
Director, Hartford Dispensary  
Hartford, CT

3:00 PM  **Break**

Prescription Drugs: Abuse and Addiction

3:20 PM  **The Availability of Controlled Substances Over the Internet**  
Robert F. Forman, PhD  
Co-Principal Investigator, Delaware Valley Node, NIDA CTN  
Assistant Professor, Department of Psychiatry, University of Pennsylvania, Treatment Research Center  
Senior Investigator, Treatment Research Institute  
Philadelphia, PA

4:00 PM  **POATS: Treating Prescription Opioid Addiction**  
Jennifer Sharpe Potter, PhD  
Research Director, Northern New England Node, NIDA CTN  
Instructor in Psychology, Department of Psychiatry, Harvard Medical School  
Belmont, MA

4:30 PM  **Discussion**  
Petra Jacobs, MD  
Medical Officer, Center for Clinical Trials Network  
National Institute on Drug Abuse, NIH  
Bethesda, MD

5:00 PM  **Adjourn**

Sponsored by The National Institute on Drug Abuse, The National Drug Abuse Treatment Clinical Trials Network (NIDA CTN).
Pre-Conference Sessions
Sunday, April 23, 2006

BEST PRACTICES FROM TREATMENT IMPROVEMENT PROTOCOL 43:
Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs

TIME: 9:00 AM – 12:00 PM

Ron Jackson, MSW
Evergreen Treatment Services
Seattle, WA

Karol Kaltenbach, PhD
MATER-Thomas Jefferson University
Philadelphia, PA

Judith Martin, MD
14th Street Clinic
Oakland, CA

These preconference sessions will be three consecutive 1-hour presentations based on topics from Treatment Improvement Protocol (TIP) 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT) produced TIP 43 to provide best-practice guidelines for the treatment and maintenance of individuals who are dependent on opioids. This TIP provides a detailed description of medication-assisted treatment (MAT) for opioid addiction in opioid treatment programs. It includes information on comprehensive treatment, medication maintenance, dosing, assessment, treatment planning for opioid addiction, and co-occurring medical and psychiatric conditions.

The three sessions are:

Tips for Counselors: Patients With Medical Problems—This session will be presented by Dr. Martin. Participants who attend this presentation will be familiar with the medical problems that are common in people who are addicted to opioids, understand the treatment of these problems in OTPs, be able to determine when to refer people to outside services and know the counselor’s role in providing supportive care for these patients.

Treating Pregnant Women in Opioid Treatment Programs—This session will be presented by Dr. Kaltenbach. Participants who attend this presentation will understand the benefits of MAT for pregnant women who are opioid addicted, be familiar with the symptoms of opioid dependence in pregnant and postpartum women, and understand methadone dosing and management for pregnant women and postpartum mothers receiving MAT.

Updates on Buprenorphine and Methadone Treatment of Opioid Addiction—This session will be presented by Mr. Jackson. Participants who attend this presentation will understand the current research on the safety and effectiveness of MAT and learn about the pharmacology and clinical use of methadone and buprenorphine.

Copies of TIP 43 will be provided to every participant, and the TIP will be used as the textbook for all three sessions.

Supported by the SAMHSA/CSAT.

STATE METHADONE AUTHORITIES’ MEETING (CLOSED SESSION – FOR STATE AND FEDERAL OFFICIALS)

TIME: 9:00 AM – 5:30 PM

Sarah Crowley
Center for Substance Abuse Treatment
Rockville, MD

Robert Lubran, MS
Center for Substance Abuse Treatment
Rockville, MD

Arlene Stanton, PhD
Center for Substance Abuse Treatment
Rockville, MD

Ray Hylton, RN
Center for Substance Abuse Treatment
Rockville, MD

Nicholas Reuter, MPH
Center for Substance Abuse Treatment
Rockville, MD

Nicolle Washington
Center for Substance Abuse Treatment
Rockville, MD

C. Danielle Johnson, MPH
Center for Substance Abuse Treatment
Rockville, MD

C. Todd Rosendale, MA
Center for Substance Abuse Treatment
Rockville, MD

State Methadone Authorities

Center for Substance Abuse Treatment staff and State Methadone Authorities will convene to discuss a variety of topics of interest to both SAMHSA and the states including disaster response, risk management, co-occurring issues, offsite treatment in residential and criminal justice facilities, the new legislation for prescription monitoring plans and the impact on confidentiality, Medicare reimbursement, treatment guidelines, and HIV/HCV issues in treatment.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
Pre-Conference Sessions

Sunday, April 23, 2006

➤ HEPATITIS EDUCATION FOR OPIOID TREATMENT PROVIDERS

TIME: 1:00 PM – 4:00 PM

Susan Simon
Hepatitis C Association
Scotch Plains, NJ

Hepatitis C Virus (HCV) is considered the most common blood-borne infection in the United States. Injection drug use accounts for more than two-thirds of all new infections in the United States. OTPs, needle and syringe exchange programs, and comprehensive risk-modifying educational programs have been shown to be effective in preventing HIV transmission and are likely to be useful for decreasing HCV transmissions.

This training will provide participants information on:

- Hepatitis C and how it affects the liver
- Hepatitis C transmission and risk factors
- Diagnostic tests
- Natural history and progression of Hepatitis C and HIV/HCV co-infection
- Treatment options

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.
Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

➤ RISK MANAGEMENT IN THE OTP

TIME: 1:00 PM – 4:00 PM

Catherine H. O’Neill, Esq.
Legal Action Center
New York, NY

Health care risk management programs emerged 30 years ago and were specifically developed as loss prevention techniques for the risks associated with accidental losses facing health care organizations. AATOD has concluded that opioid treatment programs can benefit from an effective risk management training program, in ways that are similar to the benefits that have accrued to other health care providers. Accreditation has encouraged individualized patient care and developed opportunities for programs to better organize their administrative structure, further supporting risk management.

This pre-conference session will introduce OTP administrators to the key elements of a risk management program and how they can be directly applied to OTPs. Attendees will also get the most current information available about leading legal risks to OTP operations in addition to a discussion of some critical court cases that have recently affected OTPs.

Topics to be covered include:

- What happens to the program when adverse events occur
- Scope of risk management
- Common risk identifiers
- Setting priorities
- Risk prevention and minimization
- Claims management
- Developing protective legal strategies
- OTPs’ liability for patients’ actions

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.
Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment and David Szerlip & Associates.
Pre-Conference Sessions

Sunday, April 23, 2006

➤ EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION (EUROPAD) – Heroin Addiction and Related Clinical Problems

TIME: 1:00 PM – 5:00 PM

Chairmen:
- Icro Maremmani, MD
  Pisa, Italy, EU
- Marc Reisinger, MD
  Brussels, Belgium, EU

1:00 PM  Mental Status of 1090 Heroin Addicts at Beginning of Treatment
  I. Maremmani (Pisa, Italy, EU)

1:20 PM  The Patient’s Resistance to Methadone Treatment – the Clinical and Therapeutic Aspects
  M. Pacini (Pisa, Italy, EU)

1:40 PM  Heroin Use, and the Consequences of Heroin Use, between Slovenian and Italian Heroin Addicts
  B. Lovrecic, M. Lovrecic and I. Maremmani (Ljubljana, Slovenia, EU)

2:00 PM  Methadone Maintenance: Prognostic Value of Psychopathology
  P. P. Pani (Cagliari, Italy, EU)

2:20 PM  Neonates’ Maturity in Optimal Cohort of Mothers Stabilized on Methadone for the Entire Course of Pregnancy
  L. Okruhlica, D. Klempova (Bratislava, Slovak Republic, EU)

2:40 PM  Comprehensive Methadone-Assisted Therapy: Treatment results after 2-years
  A. Kantchelov (Sofia, Bulgaria)

3:00 PM  Epidemiology and Local Monitoring: Evidence of Problematic Drug Use in Milan, Italy
  R. Mollica, C. Celata, F. Zuin, L. Bruni and R.C. Gatti (Milan, Italy, EU)

3:20 PM  A Preliminary Study for Building Some ICPs (Integrated Clinical Pathways) on Addiction Pathology: Pharmacological, Psychological, Social and Nursing Integrated Practice and the Patients’ Point of View
  A. Flego, M. Pozzi, P. Zaldera, C. Tulissi, E. Santo, E. Savoini and L. Manzan (Pordenone, Italy, EU)

3:40 PM  Designer Drugs…The Next Generation. The Scope, Effect and Challenges for Treatment, Rehabilitation and Enforcement in Israel
  M. Arieli (Jerusalem, Israel)

4:00 PM  Hepatitis C Among Patients in Three MMT Programs: Some Consequences for Hepatitis B Vaccination and Methadone Dosage
  P. Vossenberg (Deventer, The Netherlands)

4:20 PM  Substitution Treatment in Prisons
  A. Kastelic (Ljubljana, Slovenia, EU)

4:40 PM  Discussion

5:00 PM  End of Forum

In collaboration with the Italian Society of Addictions.

WELCOME RECEPTION

Sunday, April 23, 2006 5:30 PM – 7:30 PM

The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some relaxing time with old friends and colleagues not seen for too long.

THE WELCOME RECEPTION IS SUPPORTED THROUGH A GRANT FROM CEBERT PHARMACEUTICALS, INC.
National Conference Atlanta 2006

**Exhibit and Poster Sessions**

The national conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 240,000 patients in opioid treatment programs.

In order to provide exhibitors with steady exposure to conference attendees, continental breakfasts, refreshment breaks and poster sessions will be held exclusively in the exhibit area. In addition, a Networking Reception will be held Monday, April 24th to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies.

**EXHIBIT HOURS**

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, April 23</td>
<td>2:00 PM – 5:00 PM</td>
</tr>
<tr>
<td>Monday, April 24</td>
<td>7:30 AM – 12:00 PM, 3:00 PM – 7:00 PM</td>
</tr>
<tr>
<td>Tuesday, April 25</td>
<td>7:30 AM – 12:30 PM, 1:30 PM – 4:30 PM</td>
</tr>
</tbody>
</table>

Posters are in place at all times – Authors will present their topic on Tuesday, April 25th from 3:00 PM - 4:30 PM.

**EXHIBITORS AS OF NOVEMBER 1**

- American Assoc. for Treatment of Opioid Dependence
- Ammon Analytical Laboratory, LLC
- Bendiner & Schlesinger, Inc.
- CARF
- Cebert Pharmaceuticals, Inc.
- Comstock Computing LLC
- Covenant Nutritional Supplements
- CRC Health Group
- Friends Medical Laboratory, Inc.
- HCE Inc.
- Hythiam, Inc.
- JCAHO
- Mallinckrodt Pharmaceuticals
- National Institute on Drug Abuse (NIDA)
- Netaalytics
- Netsmart Technologies, Inc.
- NOVX Systems Inc.
- O. Berk Co. of New England & Kols Contain
- OraSure Technologies Inc.
- Patient Support and Community Education Project
- RTI International
- SAMHSA Substance Abuse and Mental Health San Diego Reference Laboratory
- Scientific Testing Laboratories Inc.
- Smart Management, Inc.
- The Johns Hopkins University Press
- Tower Systems Inc.
- Treatment Software Solutions
- VistaPharm, Inc.

**POSTER TOPICS INCLUDE:** (International and domestic posters will provide valuable research findings to treatment administrators and clinicians.)

- A Records Based Evaluation of the Influence Counseling Intensity Exerts Over Illicit Drug Use
- Influence of Post Traumatic Stress Disorders on Methadone Treatment Outcome
- State Policy Impact on Buprenorphine Adoption
- Factors Associated with Adherence of Participants of Multi Ethnic Backgrounds in Substance Abuse Treatment
- Buprenorphine
- Policy Implications for Methadone Use in Jails and Prisons
- Opioid Treatment and the Pursuit of Accreditation: Findings from the SAMHSA/CSAT Opioid Treatment Program Accreditation Evaluation
- CSAT Online Database for Patient Exceptions
- Relationships Between State Policies and the Availability of Services for HIV/AIDS, Hepatitis C Viral Infection and Sexually Transmitted Infections in Substance Abuse Treatment Programs
- Mothers Offering Mutual Support (MOMS): The Interverrelationship of Healing
- A Photo Journal Investigation of Treatment - A Client Perspective
- Alcohol Abuse in Narcotic Treatment Programs: Assessment & Intervention
- Adverse Exposures; Methadone Versus Other Opioids
- Improving Access to HCV Services for MMTP Clients Through Enhanced HCV Staff Training
- Resource Center A Recovery Service
- Ingestion of Methadone by Children Under Age 6
- An Examination of Patient Deaths in an OTP Over a Four-Year Period
- Predictors of Co-Occurring Mental Health Disorders in Opioid Treatment Patients
- Oxycodone Use in a Methadone Maintenance Treatment Program: A Succeeding Study Using Objective Data Results
- Providing Gender-Based Methadone Maintenance Treatment: Results from a Pilot Outcome Study
- Patient Feedback: The Key to Improving Access to the Treatment of Opioid Dependancy
- Phases of Methadone Treatment for Criminal Justice Systems
- Integrating Suboxone Therapy into an Abstinence-based, Publicly-funded Treatment System
- Opioid Prescription Abuse Among Enrollees in Opioid Treatment Programs
- Utilizing Domestic Violence Research Findings to Cross Train Opioid Dependency Staff
- Understanding Organizational Change in Opioid Treatment Programs
- New Jersey’s Heroin Initiative: A Case Study
- Enhancing Access to Methadone Treatment - A Canadian Perspective
- Prescription Opiate Patients Compared to Heroin Patients in Methadone Treatment Programs in North Carolina

The Monday Continental Breakfast is supported through a grant from Netsmart Technologies, Inc.

The Tuesday Refreshment Break is supported through a grant from O. Berk Company.

The Wednesday Continental Breakfast is supported through a grant from VistaPharm, Inc.
THE GOALS AND OBJECTIVES OF THE AMERICAN ASSOCIATION FOR THE TREATMENT OF OPIOID DEPENDENCE 2006 NATIONAL CONFERENCE ARE:

- To identify and provide new information of critical importance to the field
- To examine and evaluate the implications of new information for clinicians, administrators, and policy makers
- To demonstrate techniques for improving clinical and program administration

Monday, April 24, 2006

➤ OPENING PLENARY SESSION

NATIONAL POLICY INITIATIVES – TREATING PEOPLE WITH DIGNITY

TIME:  8:45 AM – 10:15 AM

Speakers:
Terry L. Willis, MS, Conference Chair, Chief Executive Officer, Georgia Therapy Associates, Inc.
Minister DeBorah M. Evans, Atlanta, GA
Neil Kaltenecker, Director, Department of Human Resources Division of Mental Health Developmental Disabilities and Addictive Diseases
Honorable Randall Mangham, Representative, Georgia State Legislature
Mark W. Farrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc.
Honorable John P. Walters, Director, White House Office of National Drug Control Policy

The opening plenary introduces the theme of the 2006 national conference, “Treating People with Dignity – Working with Criminal Justice and Health Care Systems.” Medication Assisted Treatment (MAT) has long been recognized as the most successful models for treating opioid addiction in the United States. A key element of national, state and local drug strategies, MAT seeks to assure delivery of treatment that is appropriate, effective and compassionate. The session’s distinguished panel will welcome participants to Atlanta, and will discuss initiatives in Georgia, the southern region, and the nation to increase access to opioid treatment, improve treatment and prevention systems, and expand collaboration with criminal justice and health systems in drug demand and reduction efforts. The nation’s “Drug Czar,” presidential cabinet member John P. Walters, Director of the White House Office of National Drug Control Policy, provides the Keynote address.

➤ WORKSHOP SESSIONS

Workshops will offer participants a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

NOTE: Basic Track Workshops

Basic Track: This year we will again be offering a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend all six sessions listed will receive a special certificate of completion.

Basic Track Workshop Sessions: A1, B1, C1, D1, E1, and F1

WORKSHOP SESSIONS

TIME:  10:30 AM – 12:00 NOON

A – 1

The History of Narcotic Control Policy and the Treatment of Opioid Dependence:
Old Lessons for New Practitioners and Patients
Sarah Rockwell Podolin, LSW, MATER-Thomas Jefferson University, Philadelphia, PA
The history of narcotic use and control in America will be examined. Social, professional and political forces that influenced narcotic control policy and treatment will be identified and lessons of the past will be applied to the current climate in which narcotic control policy and treatment is developed and conducted.

* Note: Basic Track
A – 2
Methadone Maintenance Treatment and Reentry for Prisoners
Timothy W. Kinlock, PhD, Friends Research Institute, Inc., Baltimore, MD; Terrence T. Fitzgerald, MD, Man Alive, Inc., Baltimore, MD; Gary Sweeney, CACAD, Man Alive, Inc., Baltimore, MD
This workshop will describe the preliminary results of a randomized clinical trial studying the effectiveness of initiating inmates with histories of heroin addiction on methadone maintenance treatment as they near release and continuing in the community. The practical medical and counseling aspects of program implementation will also be presented.

A – 3
Benzodiazepine Use in Opiate Dependent Populations
Robert L. Walsh, BS, National Institute of Health, Bethesda, MD; Joseph Gregory Liberto, MD, Baltimore, VA Medical Center, Baltimore, MD; Richard Steven Schottenfeld, Yale University, New Haven, CT
Many patients who present for opiate treatment also abuse benzodiazepines, which are commonly involved in deaths related to misuse/abuse. This highly interactive workshop will discuss the nature and extent of benzodiazepine abuse, how it affects treatment outcomes in opiate dependent individuals who abuse benzodiazepines and the current treatments for benzodiazepine abuse.

A – 4
A Harm Reduction Approach to Retaining Challenging Populations in Opioid Treatment
Basha Closic, BA, Brandywine Counseling, Inc., Wilmington, DE; Jeremy Zane, BA, Brandywine Counseling, Inc., James Harrison, MHS, Brandywine Counseling, Inc., Wilmington, DE
Continued illicit drug use, in many OTPs, results in disciplinary action, including discharge. A modification of ‘Safety Counts’ attempts to improve these patients’ success. Information on the intensive interventions aimed at reducing harmful or risky behavior, the program’s benefits, necessary resources and interaction with the larger treatment program will be presented.

A – 5
Pervasively Communicating Research and Policy Recommendations to Key Local, State and Federal Decision Makers
John T. Carnevale, PhD, Carnevale Associates, LLC, Darnestown, MD; Jennifer Duncan Collier, JD, Washington, DC
Opioid-based treatment is one of the best researched drug treatments in the world, but government officials and policy makers continue to doubt its effectiveness. This workshop will help researchers and providers learn how to translate research and best practice into practical policy recommendations and effectively communicate these recommendations to decision-makers.

WORKSHOP SESSIONS
TIME:  1:30 PM – 3:00 PM

The Role of the Nurse in OTPs
Maureen Alves, LPN, Center for Behavioral Health Rhode Island, Johnston, RI; Theresa Steinbacher, LPN, Center for Behavioral Health Indiana, Fort Wayne, IN; Rhonda Holoman, LPN, Center for Behavioral Health Louisiana, Shreveport, LA
This workshop will explore the multifaceted role of the nurse in OTPs. It will address the skills and training needed to assist nurses in their changing responsibilities and discuss the strengths and limitations associated with occupying a dual role of counselor/nurse. Evolving requirements for registered nurse vs licensed practical nurse will also be discussed.

Expanding and Strengthening Baltimore’s Opioid Treatment Programs
Adam Brickner, BA, Baltimore Substance Abuse Systems, Inc., Baltimore, MD; Elaine Swift, PhD, Baltimore Substance Abuse Systems, Inc., Baltimore, MD; Michael Douglas, MHS, Baltimore Substance Abuse Systems, Inc., Baltimore, MD
This presentation will discuss Baltimore’s heroin problem and provide a history of the creation of its non-profit substance abuse authority then go on to describe “DrugStat” – the OTP performance improvement process launched by that agency. The integration of buprenorphine into OTPs in the Baltimore area will also be discussed.

Developing and Implementing a Pro-Active Media Strategy
Gerald Migliore, Media Consultant, Englewood, NJ
This workshop will provide agency directors and/or designated public relations staff with the ability to develop and implement pro-active media and marketing public relations strategies designed to improve the public’s understanding of opioid dependence and medication assisted treatment.
HOT TOPIC ROUND TABLES

TIME: 1:30 PM – 3:00 PM

Hot Topic Round Tables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

• Impact of Domestic Violence
• Federal Regulatory Issues and Patient Care
• Alcohol Abuse and MAT

• Improving Retention: Developing Partnerships Between Provider and Patient
• Interacting with Fellowship Groups
• Accessing Residential Care and Housing

WORKSHOP SESSIONS

TIME: 3:30 PM – 5:00 PM

B – 1
Medical Aspects of Methadone: What Counselors Need to Know about the Medication
Judith Martin, MD, 14th Street Clinic, Oakland, CA
This workshop will review the basic elements of opioid agonist treatment, such as dose, side effects and duration of MMT. It will cover pharmacologic aspects such as half-life, receptor site, blood level and rapid metabolizer. It is intended to provide a language to engage the patient who is concerned about his or her medication.

* Note: Basic Track

B – 2
OTP Interface with the Criminal Justice System
James Carleton, MS, CODAC Behavioral Healthcare, Cranston, RI
This workshop focuses on the relationship between OTPs and incarcerated population, from the viewpoint of a working, viable program. A series of digital interviews with primary stakeholders explore the dynamics of multi-agency systems, often with superficially competing agendas, working towards a common goal: treatment of incarcerated OTP patient. The working model is thoroughly discussed and illustrated.

B – 3
Opioid Prescription Abuse Among Enrollees in Opioid Treatment Programs
Andrew Rosenblum, PhD, National Development and Research Institutes, New York, NY; Mark Parrino, MPA, American Association for the Treatment of Opioid Dependence, New York, NY; Carleen Maxwell, MPH, American Association for the Treatment of Opioid Dependence, New York, NY
We will report findings from an on-going three-year project on prescription opioid abuse, involving all patients enrolling in > 70 OTPs, representing all regions of the United States. Primary focus will be on patient and regional factors associated with prescription opioid abuse and the implications this has for OTPs.

B – 4
Patient and Provider Groups: Methods and Models
Paul Bowman, CMA, Massachusetts NAMA, North Quincy, MA; Donna Schoen, MCA, Long Island NAMA, New Hyde Park, NY; Sharon P. Dembinski, PNP, Webster, MA
Patient representation and committees are becoming more common. Forms, functions, and goals vary. This workshop, presented by a panel of NAMA advocates, describes operations and successes of three different types of patient committees, including a discussion of factors that make them “work”, especially support by provider staff.

B – 5
Methadone and Overdose Prevention
Randy Seewald, MD, Beth Israel Medical Center, New York, NY; Sharon Stancilff, MD, Harm Reduction Coalition, New York, NY; Sarz Maxwell, MD, Chicago Recovery Alliance, Chicago, IL
Drug users experience morbidity and mortality from accidental drug overdose. Learn how methadone treatment prevents overdose and hear an update on prevention, including reviews of heroin overdose physiology and epidemiology and overdose prevention training (including risk factors, recognition, intervention, and a brief video on naloxone use).
MIDDLE PLENARY SESSION

MEDICATION ASSISTED TREATMENT & THE CRIMINAL JUSTICE SYSTEMS

TIME:  8:45 AM – 10:15 AM

Moderator:
Paul Samuels, Esq., President and Executive Director, Legal Action Center

Speakers:
Timothy Ryan, Chief of Corrections, Orange County, Florida
Honorable Martin Horn, Commissioner, New York City Department of Corrections

For decades, drug treatment and criminal justice were perceived to be at opposite ends of the national and local drug policy spectrum. Moderated by Paul Samuels, Esq., President and Executive Director of the nationally renowned Legal Action Center, this plenary session will highlight the emerging and ground-breaking partnership between medication assisted treatment (MAT) and criminal justice systems, moving closer together in purpose and mission to improve service delivery. The expert panel will present exciting initiatives that have increased access to methadone treatment in jails and enhanced education and information flow to drug court judges and administrators. Legal, ideological and funding impediments to MAT access in criminal justice settings will be explored, and innovative models developed and undertaken in several States will be shared.

WORKSHOP SESSIONS

TIME:  10:30 AM – 12:00 NOON

C – 1
Culture Counts: Fostering a Culturally Competent System of Care
Michael Freeman, MS, Connecticut Counseling Centers, Inc., Waterbury, CT; Diane Heyward, MS, Connecticut Counseling Centers, Inc., Waterbury, CT; Nydia Diaz, Connecticut Counseling Centers, Inc., Waterbury, CT

This workshop will explore the process of fostering a culturally competent system of care; provide an overview of the challenges in providing culturally competent and recovery-oriented treatment with limited human and financial resources; and will highlight the evolution of cultural diversity within a methadone maintenance treatment program.

* Note: Basic Track

C – 2
The Homeless Mentally Ill Methadone Patient in Rikers Island Jail. Keep NYC Program: A Pilot Project for Housing, Medical and Social Services After Release to the Community
Pat Precin, MS, New York Institute of Technology and Pathways to Housing, Inc., New York, NY; Herman Joseph, PhD, Rockefeller University, New York, NY; Kathleen Coughlin, BA, New York City Department of Corrections, New York, NY

A project addressing community needs of incarcerated homeless mentally ill methadone patients in Rikers Island Jail KEEP will be presented. Topics discussed include planning, cooperation of community agencies to establish the pilot, medical and social problems, treatment and resolution of issues, and initial outcomes.

C – 3
Methadone Maintenance Treatment and Older Adults
Carolyn M. Drennan, MA, Beth Israel Medical Center, New York, NY; Randy Seewald, MD, Beth Israel Medical Center, New York, NY; Patti Juliana, LCSW-R, Beth Israel Medical Center, New York, NY

This presentation reviews the medical, mental/cognitive health, social, financial and legal factors involved with working with older patients in methadone maintenance treatment. Suggestions for future interventions, policy changes and specific programming will be offered, and future research will be discussed. This presentation is intended for drug treatment providers.

C – 4
Building Communication Bridges Between Child Protective Services and Drug Treatment Providers
Hendree Jones, PhD, Johns Hopkins University, Baltimore, MD; Karol Kaltenbach, PhD, Thomas Jefferson University, Philadelphia, PA; Peter Selby, MD, St. Joseph’s Health Center, Toronto, ON

This workshop examines relationships between Child Protective Services (CPS) and drug treatment facilities treating pregnant and post-partum women. Highlights include reviewing conflicting priorities of CPS and treatment, impact of laws on treatment outcomes and tools to educate patients, CPS and drug treatment providers to best facilitate relationships between these entities.
Establishing and Strengthening Ties with the Addiction Recovery Community
Lisa Mojer Torres, JD, Faces & Voices of Recovery, Washington, DC; Patricia Taylor, BA, Faces & Voices of Recovery, Washington, DC; Alice Diorio, Opiate Dependence Resource Center, Brattleboro, VT

An emerging national recovery movement is building a recovery-oriented continuum of care. This workshop will provide ideas to bring patients information on their rights and engage them with recovery community organizations and recovery advocates (including local, regional and national recovery community organizations, as a support resource during early treatment.

WORKSHOP SESSIONS

TIME: 1:30 PM – 3:00 PM

D – 1
Using an Evidence-based Program to Treat Stimulant Abusers – The Matrix Model
Jeanne L. Obert, MFT, The Matrix Institute, Los Angeles, CA
This workshop will compare the treatment needs of Cocaine and Methamphetamine abusers in order to determine whether differences need to be taken into account when designing effective treatment interventions for stimulant abusers. The Matrix Model, a structured outpatient treatment protocol that has been proven effective when used with stimulant abusers, will be described in detail.

*D Note: Basic Track

D – 2
A Public Health Approach to Implementing OTP’s in Correctional Settings
Carmen Albizu Garcia, MD, Center for Investigation and Sociomedical Research, San Juan, PR; Gregory Warren, MBA, Maryland Department of Public Safety and Correctional Services, Baltimore, MD; Victor A. Torano Gonzalez, MD, Puerto Rico Department of Correction & Rehabilitation, San Juan, PR
This workshop will describe how the Maryland Department of Public Safety and the Corrections Administration in Puerto Rico have planned for and implemented methadone treatment in the Baltimore City Detention Center and in a prison in San Juan. The presenters will describe their practical experiences and lessons learned.

D – 3
Integrating Recovery-Oriented Standards of Care into MMTP: Cultivating a Culture of Recovery
Alan Lee Nolan, LCSW, Connecticut Counseling Centers, Inc., Waterbury, CT; Michael Freeman, MS, Connecticut Counseling Centers, Inc., Waterbury, CT; Marshall Rosier, MS, Connecticut Counseling Centers, Inc., Waterbury, CT
This workshop will demonstrate the value of cultivating a person-centered culture of recovery within a MMTP setting. Through the examination of an alternative model, presenters will discuss person-centered recovery alliances and partnerships, facilitating empowerment, and the identification of resources needed for creating a self-directed recovery action plan.

D – 4
Evidence-Based Practices in Opioid Treatment: A Comprehensive Technology Transfer Model
Stephen J. Gumbley, MA, Addiction Technology Transfer Center of New England, Providence, RI; Denise M. Howard, BA, Discovery House, Providence, RI
This workshop will present an overview of the ATTC-NE’s comprehensive model for transferring research to practice. The applicability of the transtheoretical change model to organizations, and its relationship to the implementation process, will be discussed. Participants will have an opportunity to practice the methodology and utilize examples drawn from clinical experiences.

D – 5
When Substance Abuse Affects Others: A Six-Skills Model for Survival and Change
Jan Ligon, PhD, Georgia State University, Atlanta, GA
This session will provide an overview of a simple and straightforward model involving six skills that may be helpful to those who are affected by a substance abuser. Handouts will provide information on the model, materials for use with clients, and an evaluation form to assess effectiveness.

THE 2006 INTERNATIONAL LUNCHEON ON TUESDAY, APRIL 25
IS SUPPORTED THROUGH A GRANT FROM COLONIAL MANAGEMENT LP
AND DAVID SZERLIP & ASSOCIATES, INC.
Dr. James S. Dorsey is the Medical Director of the American Therapeutic Association Methadone Clinic in Sparks, Nevada and Professor Emeritus at the University of Nevada Medical School. For the 35 years he has advocated for methadone treatment. He has been involved in physician training for attending and resident physicians. In 1990 he received the ASAM Award in Physician Education and Certification. He has been involved in methadone treatment since 1986 and has co-authored articles with Dr. Jerome Jaffe and Dr. Loretta Finnegan. Dr. Chappel is described as a person who is kind, unassuming, and eloquent who exhibits great care when seeing patients.

Don C. DesJarlais, PhD

Dr. Don DesJarlais is the Director of the Baron Edmond de Rothschild Chemical Dependency Institute at Beth Israel Medical Center, a Research Fellow with the National Development and Research Institutes, Inc. and Professor of Epidemiology with the Department of Epidemiology and Population Health of Albert Einstein College of Medicine. He has published over 425 articles and conducted over 1,500 presentations. He consistently helps the field understand the psychological and social aspect of the disease. His work has demonstrated conclusively and compellingly that treatment of opiate dependence is an absolute necessity in the face of the HIV crisis.

James S. Dorsey, MD

Dr. James S. Dorsey is the Medical Director of the Adult Addiction Opioid Program of the Anne Arundel County Department of Health. Through his efforts he ensured the continuation and expansion of medication assisted treatment. He continually seeks opportunities to educate; patients, politicians, community leaders, local and national health care providers on the efficacy of medication-assisted treatment. As a researcher and clinician he has made a significant contribution to the body of literature in the areas of pain management in methadone patients and in optimum dose levels. He is a strong promoter of “science to service” and evidence based practices.

David A. Fiellin, MD

Dr. David A. Fiellin is an Associate professor of Medicine at Yale University and a Robert Wood Johnson Generalist Physician Faculty Scholar. His extensive scholarly work is focused on the interface between primary care and substance abuse. He has published several key articles on methadone patient treatment in medicine's best journals. He conducts research on the transfer of treatment strategies, including opioid agonist maintenance with methadone and buprenorphine, from specialized settings to office-based, primary care, and HIV specialty settings. He is a role model of the highest standard for trainees in medicine including medical students, residents, fellows and junior faculty.
William B. Miller, MD  Pennsylvania  
Dr. William B. Miller is the Medical Director of TADISO, Inc. Responding to the growing heroin epidemic and mindful of the controversies surrounding methadone treatment and community resistance, Dr. Miller opened a clinic in 1969 in one of Pittsburgh’s toughest neighborhoods. At the age of 83 with 36 years of service he continues to provide treatment in a quiet understated manner devoid of negativism and judgment. Recognized by his peers, his career is a testament to those who first embraced methadone as a valued treatment for addiction to opiates. A recipient of many awards, he continues to serve 650 patients.

Lubomir Okruhlica, MD  Slovak Republic  
Dr. Lubomir Okruhlica is the Director of the Centre for Treatment of Drug Dependencies in Bratislava of the Slovak Republic. He established the first maintenance program in Slovakia, at first with codeine. Later on he established the methadone maintenance treatment program at the Centre for Treatment of Drug Dependencies in Bratislava 1997. Dr. Okruhlica is in charge of a central, specialized health institution for treatment and research of health related problems associated with psychoactive substance use, predominantly for dependencies. He is actively involved in the international cooperation and organization of the field, especially in the Central European region.

Tyrone Patterson, CAC-II  Washington, DC  
Tyrone Patterson is the Manager of Addiction Prevention and Recovery Administration Model Treatment Clinic in Washington, DC. Mr. Patterson has been providing dedicated service to methadone patients for over 30 years. Model Treatment under Mr. Patterson’s able leadership was one of the first methadone CARF certified clinics. His command of the theoretical and the practical provision of substance abuse services have served to further the legitimacy of District of Columbia methadone treatment programs. Mr. Patterson is a champion of compassionate treatment for opiate addicts. Mr. Patterson is described by his colleges as an efficient and effective manager and leader.

Jina Thalmann, MSW  Florida  
Jina Thalmann is the Program Director of the Opioid Dependency Treatment Program in Orlando, Florida. Ms. Thalmann has been a leader in the field for the treatment of opiate dependency in the correctional setting. She took the lead in 2001 by developing the Methadone Program for the Orange County Jail in Orlando, Florida. Because of her work Orlando has the only residential program in Central Florida that allows methadone maintenance patients to participate in their program. Additionally, her work with the Drug Court has impacted the practice of allowing patients in Drug Court to be on methadone or buprenorphine.

Terry Willis, MS  Georgia  
Terry Willis is Chairman of the Board of the Opioid Treatment Providers of Georgia and CEO of Georgia Therapy Associates, Inc. When Terry became Chairman of the OTPG, the state of Georgia and the treatment providers were in an adversarial relationship. Terry’s efforts broke down the atmosphere of distrust. He forged a partnership whereas the State officials and treatment providers are working partners. The adversarial to advocacy concept has paved the way for grants for the study of HIV and Hepatitis testing. We are here tonight because of Terry's tireless efforts to bring this great conference to this great city.

FRIEND OF THE FIELD AWARD
The prestigious Friend of the Field Award was established by the American Association for the Treatment of Opioid Dependence Board of Directors. This award recognizes extraordinary contributions to the field of methadone treatment by an individual or institution whose work, although not directly related to methadone treatment, has had a significant impact on our field. The 2006 Friend of the Field Award has been awarded to:

Kimberly A. Johnson, MS  Maine  
Director, Maine Office of Substance Abuse  
Ms. Kimberly Johnson serves as the Director of the Maine Office of Substance Abuse. She has been an indefatigable advocate of methadone treatment programs in Maine during a turbulent period of development. Maine did not have methadone treatment programs within its boundaries until 1995. Ms. Johnson has provided extraordinary and consistent leadership in resisting the efforts of community groups and elected officials in closing methadone treatment programs in addition to fending off legislation, which would have had a negative impact on the evolution of methadone treatment programs in Maine and the Northeast corridor. Ms. Johnson also has the distinction of being the only State Alcohol and Drug Abuse Director to spearhead a major public relations campaign, through radio and other media outlets, to specifically support the methadone treatment system. The continued use of methadone treatment in Maine would have been seriously threatened were it not for Ms. Johnson’s leadership in the face of such extraordinary challenge.

THE 2006 AWARDS BANQUET IS SUPPORTED THROUGH A GRANT FROM MALLINCKRODT, INC.
WORKSHOP SESSIONS

TIME: 8:00 AM – 9:30 AM

E – 1
Integrating the Skills and Spirit of Motivational Interviewing
Robert C. Lambert, MA, Connecticut Counseling Centers, Norwalk, CT
This workshop will include a brief conceptual overview of Motivational Interviewing, a review of core principles, and an introduction to specific counseling skills. The presenter will also provide the clinician with a roadmap for the successful integration of the Motivational Interviewing style with their current clinical approach and existing clinical culture where they work.

* Note: Basic Track

E – 2
Women in the Middle: How to Collaborate and Negotiate Prison Systems to Provide MAT Care for Opioid Dependent Women (OPW) Behind the Walls
Jeneane Burke, MSN, MATER, Thomas Jefferson University, Philadelphia, PA; Kate Vandegrift, MA, MATER, Thomas Jefferson University Hospital, Philadelphia, PA
This workshop will focus on barriers and solutions in treating incarcerated OPW; the need to partner with all levels of care in providing medically accepted treatment; integrating and developing methods of communication within systems that have individual missions, goals and objectives, and restrictions that present challenges in accomplishing best practice outcomes.

E – 3
Drug Interactions Among Medications for the Treatment of Drug Addiction and for HIV/HCV Infections
Jag H. Khalsa, PhD, National Institute on Drug Abuse, Bethesda, MD; David J. Greenblatt, MD, Tufts University School of Medicine, Boston, MA; Evan D. Kharasch, MD, University of Washington School of Medicine, Seattle, WA
The presenters will discuss the incidence of drug-drug interactions, the mechanisms of these interactions, specific issues of drug-drug interactions when treating with methadone or buprenorphine, as well as with other psychotropic medications, ways of predicting when an interaction may occur, the consequences of an interaction and appropriate interventions when an interaction occurs.

* Sponsored by NIDA

E – 4
How We Measured Costs, Cost-Effectiveness, and Cost-Benefit of OTP Accreditation
Brian T. Yates, PhD, American University, Washington, DC; Danyelle Mannix, BA, American University, Washington, DC; Namratha Swamy, PhD, Northrop-Grumman Health Information Technologies, Rockville, MD
In this workshop, participants will be able to create a Cost Procedure Process Outcome Analysis (CPPOA) model based on both the 1999 NIDA manual for (CPPOA), and the OTP accreditation evaluation for their own OTP. Participants will learn how distinctions between costs, processes, and outcomes can provide a framework for evaluating programs.

E – 5
Attempted Suicide and Accidental Overdose in Methadone Maintenance Patients
Gloria Baciewicz, MD, University of Rochester, Rochester, NY; Mary Ellen Ross, RNC, University of Rochester, Rochester, NY
Overdose and suicide are leading causes of death among treated opiate users. This workshop reviews research on risk factors for suicide and unintentional overdose, presents results of a survey of these behaviors among a local sample of MAT patients, and provides guidance in risk assessment, prevention, and intervention.
Wednesday, April 26, 2006

WORKSHOP SESSIONS

TIME: 9:45 AM – 11:15 AM

F – 1

Psychiatric Comorbidity

Joan E. Zweben, PhD, 14th Street Clinic/East Bay Community Recovery Project, Oakland, CA

This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the methadone treatment program. We will discuss addictive behavior and coexisting psychiatric problems, barriers to addressing them, how to educate the clients appropriately, how to prioritize treatment tasks, and how to work with physicians around psychotropic medication.

* Note: Basic Track

F – 2

Integration of Buprenorphine Treatment in Opioid Treatment Programs

C. Danielle Johnson, MPH, US Department of Health and Human Services, Rockville, MD; Charles W. Walton, MD, Discovery House-Utah, Inc., Salt Lake City, UT; Marian Currens, BSN, Center for Addiction Medicine, Baltimore, MD

Although OTPs are permitted to treat patients with buprenorphine, only a limited number have chosen to adopt this treatment modality. This workshop will explore the advantages and challenges of the use of buprenorphine in the OTP setting. The issues to be covered include cost, stigma, and a variety of clinical issues.

F – 3

Paying it Forward: The Utilization of Contingency Management and Motivational Enhancement Therapy with the Resistant Patient

Michael Gaudet, LICSW, Center for Behavioral Health Rhode Island, Johnston, RI; Rainer Franke, MA, Denver Behavioral Health Center-Downtown, Denver, CO

There are many manifestations of resistance which often result in a tug-of-war between patient and counselor. This workshop will explore ways in which the principle of Motivational Enhancement can be incorporated into the philosophical and practical framework of Contingency Management, and how this will be beneficial to the resistant patient.

F – 4

Optimizing Cardiovascular Health and Safety in Methadone-Maintained Patients

Mori Krantz, MD, University of Colorado Denver Health Medical Center, Denver, CO; John Schmittner, MD, National Institutes of Health, Baltimore, MD

This roundtable workshop will review the dose-related effects of methadone on QTc prolongation, risk of torsades de pointes implied by QTc change, indications for electrocardiography, effect of medications affecting hepatic cytochrome P-450 3A4 enzymes, and strategies to weigh the benefits of methadone against the individual patient’s cardiac risk factors.

F – 5

In the Door / Care in 24: Improving Access and Retention

Janet Bardossi, LCSW, CODA, Inc., Portland, OR; Jeanine Bassett, MA, CODA, Inc., Portland, OR

In 2004, CODA started using Process Improvement Strategies in its methadone services with remarkable success. One recent project helped reduce intake waiting times from days to hours. This presentation will focus on practical examples of implementing rapid cycle change strategies to improve care. Promises to be fun and informative application for practice.

➤ CLOSING PLENARY SESSION

THE FUTURE OF MEDICATION ASSISTED TREATMENT - SPIRITUAL AND POLITICAL VIEWS

TIME: 11:30 AM – 12:45 PM

Speakers:
Terry L. Willis, MS, Conference Chair, Chief Executive Officer, Georgia Therapy Associates, Inc.
Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc.

Over the past decade, the important role of evidence-based, holistic medication assisted treatment (MAT) has been promoted in our national drug policy. Patient progress viewed daily, and positive outcomes of MAT documented in 40 years of research, serve as ongoing inspirational sources for providers and patients in commitment to their work. The closing plenary session will provide a unique view to the science of addictive disease, the importance of holistically treating the “addict as patient,” and knowledge of MAT’s important contribution to the public health, now and in the years to come. Mr. Willis and Mr. Parrino and other nationally renowned policy makers will advance the themes of this closing plenary session.
HYATT REGENCY ATLANTA  
265 Peachtree Street NE  
Atlanta, Georgia 30303-1294  
404-577-1234  
FAX: 404-588-3740  
RESERVATIONS: 800-233-1234

Hyatt Regency Atlanta, the first contemporary atrium hotel in the world, reinvented modern hotel architecture when it transformed itself with a total renovation and expansion in 1996. In the heart of downtown, Hyatt’s 23-story flagship hotel is one of the premier meeting destinations in the US. Offering nearby shopping and convenient access to America’s Mart, Georgia World Congress Center, and Georgia Dome, it is ideally located among hotels in Atlanta, Georgia.

The familiar blue dome soars over an exclusive downtown address right on Peachtree Street.

Hyatt Regency Atlanta offers each guest an opportunity to enhance their stay and keep active at a number of recreation facilities, right on the hotel grounds.

Sleeping rooms have been reserved for conference attendees at a rate of $149 single/double occupancy plus applicable taxes. This reduced rate is available until March 30, 2006. Reservation requests received after the cut-off date of March 30, 2006 will be based on availability at the Hotel's prevailing rates.

To reserve a room at the group rate, contact the hotel directly by calling their reservation line at 404-577-1234 or 800-233-1234. Please be sure to reference the American Association for the Treatment of Opioid Dependence, Inc. or AATOD National Conference. Reservations can also be made on-line through the AATOD website by clicking on the Hotel Reservations link.

Swimming Pool:
After a long day of meetings, there is nothing more refreshing than going for a swim. The pool is located outdoors on the Ballroom Level and is open seasonally from 7:00 AM to 10:00 PM.

Take an invigorating dip in the swimming pool, visit the 5,000 square-foot Fitness Center or enjoy a round of golf at one of Atlanta's excellent golf courses. Florist and Gift Shop are available on-site. Information about professional baby sitting services is also available.

Fitness Center:
Enjoy the contemporary 5,000 square-foot Fitness Center located next to the Ivy Tower elevator. The Fitness Center is equipped with:

- Six treadmills
- Five stair machines
- Four Lifecycles
- Free weights
- Circuit weights

To enhance your time at the Fitness Center, included is a cardio-entertainment center, unlimited towels, vending machines and an attendant on duty. Come get away from it all, anytime between 5:00 AM and 11:00 PM.

In addition, for spa services, the Peachtree Athletic Center is available for guests of Hyatt Regency Atlanta.

TRAVEL INFORMATION
World Travel, Inc. has been designated the Official Travel Coordinator for the 2006 American Association for the Treatment of Opioid Dependence Conference. We recommend that you contact World Travel Group Department at 800-867-2970 (Monday – Friday, 8:00 AM –5:30 PM EST) for your transportation and car rental needs. Please identify yourself as American Association for the Treatment of Opioid Dependence or AATOD Conference Attendee. World Travel will make all reservations based on the lowest fare available on date of issue.

GROUND TRANSPORTATION
The Hyatt Regency Atlanta hotel is 15 minutes from Hartsfield-Jackson Atlanta International Airport (ATL). Taxi rates are as follows:

<table>
<thead>
<tr>
<th>Flat Rate Zone from Hartsfield To Downtown</th>
<th>1 person</th>
<th>2-3 persons</th>
<th>4-6 persons</th>
<th>7 or more persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25.00</td>
<td>$26.00</td>
<td>$30.00</td>
<td>$40.00</td>
<td></td>
</tr>
<tr>
<td>($13 ea.)</td>
<td>($10 ea.)</td>
<td>($10 ea.)</td>
<td>($10 ea.)</td>
<td></td>
</tr>
</tbody>
</table>

Other transportation options, other than taxis, are:

The Atlanta Link – the sole shuttle operator at the airport that serves Downtown, Midtown and Buckhead. Once in baggage claim follow the signs outside to ground transportation and hotel shuttles. You can pay with cash or credit card in advance on the website or to the dispatcher on the curb. The cost is Downtown $16 (1 way), & $28 (roundtrip), Midtown $18 & $32 and Buckhead $20 & $36. They do runs to & from the hotels twice an hour from 6am-12am. For more info, www.theatlantalink.com or 404-524-3400.

The Marta -- once in baggage claim follow the signs to Marta. Take the northbound train to the Peachtree Center Station stop. Exit the train and take the escalator up towards Peachtree Center Mall. Follow signs to the covered walkway into the hotel. The cost for a one way trip is $1.75 but you can get deals on extended stay visitor passes. For more info on train routes and schedules go to www.itsmarta.com.
Listen closely, do you hear the sounds in the air? It is the City of Atlanta calling you near Right Here! Right Now! It’s possible, you can Experience the wonders and the excitement of Atlanta’s fair land Awaken each day to fun filled events It is a must that you are showered with the best of the best Like the Botanical Gardens, full in bloom Let your nose be tickled by each delicate perfume Catch a baseball game with the Atlanta Braves Be a true fan and join the wave Historical sites cannot be ignored, there is.. The Fox Theatre; The Carter Center; The home of Martin Luther King Jr. and more. Six Flags over Georgia harbor a whirlwind of thrills Where family and friends can ride from morning until… Blissful sights await your kind eye Like Lake Lanier and Stone Mountain, where the kids love The train rides Relax a little and take a moment or two Indulge in a game of golf and perhaps a wine tour The perfect place to do these leisurely things Would be Chateau Elan, Atlanta’s famous winery Do you like to shop for a little of nothing or free? If so, just sign up for our guided shopping spree Take in a play at Agatha’s Mystery PlayHouse Where you can eat, drink and even act in the play itself Dinner and dancing you cannot resist There is the Underground and there is also Buckhead Jazz it up or jazz it down At Dantes Down the Hatch and Church Hill Ground The Fox Theatre, Coca Cola Building and CNN too All of these phenomenal attractions are calling for you So check with hospitality for the when, where and how And don’t forget to ask about our SPECTACULAR discounts Now what are you waiting for? Plan in advance!! And if this is your first trip to Atlanta, it won’t be your last Reserve your travel by ground, air or train Because in April 2006, the GRAND festivities begin!! So don’t miss this opportunity to mingle with the best of The Georgia Peaches!!

For more information, visit the official travel information for visitors at www.atlanta.net, call toll-free 800-Atlanta or 404.521.6600. You can also visit the Official Visitor Center at 233 Peachtree Street NE, Suite 100, which is around the corner from the Hyatt Regency Atlanta.
CONFERENCE REGISTRATION
Registration for the American Association for the Treatment of Opioid Dependence, Inc. (AATOD) annual conference can be done on-line by visiting the AATOD website at www.aatod.org or by completing the registration form and faxing it to 856-423-3420 or by mailing it to:

AATOD Annual Conference Registration
c/o Talley Management Group, Inc.
19 Mantua Road
Mt. Royal, New Jersey 08061

If faxing your registration, DO NOT mail the original form, doing so may result in duplicate charges to your credit card! Should you have any questions regarding conference registration please call 856-423-3091.

CONTINUING EDUCATION CREDITS
• AATOD, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB).
• AATOD is an approved provider through NAADAC, The Association for Addiction Professionals (Provider #000218).
• Application to award Continuing Education Units (CEUs) will be submitted to the following organizations:
  New York State Nurses Association’s Council on Continuing Education, which is accredited by the American Nurses’ Credentialing Center’s Commission on Accreditation.
  Georgia Psychological Association to award CEUs to psychologists.
  National Board of Certified Counselors.
  Alcohol and Drug Abuse Certification Board of Georgia.
Note: The Georgia Addiction Counselors Association Certification Board accepts NAADAC-approved training hours.
Registration Information and Fees

HOW TO REGISTER:
Registration can be made on-line at www.AATOD.org and clicking the ON-LINE REGISTRATION LINK or by completing the Registration Form and mailing or faxing to the address provided.

<table>
<thead>
<tr>
<th>Full Conference Registration*</th>
<th>1 Person from an agency</th>
<th>2 or more from an agency, each</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standard Registration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>November 1, 2005 – March 17, 2006</td>
<td>$485.00</td>
<td>$450.00</td>
</tr>
<tr>
<td><strong>On-Site</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 22, 2006</td>
<td>$510.00</td>
<td>No Group Discount Applies</td>
</tr>
</tbody>
</table>

* Includes: Admission to Pre-Conference Sessions (excluding CMA Training Course, Buprenorphine Course and Clinicians Course), Welcome Reception, all Plenary Sessions, Workshops, daily continental breakfast, daily afternoon breaks, Exhibit Hall, Networking Reception and Awards Banquet.

There can be no conference registration fee splitting. Only one discount per conference participant is allowed, including the presenter’s discount.

GROUP DISCOUNTS DO NOT APPLY FOR THE FOLLOWING CATEGORIES:

**Single Day Registration**
(Does NOT include Awards Banquet) ......................................................... $ 215.00

**Clinicians Course**
(Includes Welcome Reception) ................................................................. $ 150.00

**Additional Awards Banquet Tickets**
(Must Purchase on site) ........................................................................ $ 65.00

**Additional Welcome Reception Tickets**
(Must purchase on site) ........................................................................ $ 20.00

**CME / CEU Fees (These fees are not included in full conference registration fee)**
Physicians / Physician Assistants / Pharmacists ................................. $ 40.00
Nurses / Social Workers / Psychologists ............................................... $ 30.00
Counselors ............................................................................................... $ 20.00

**Special Needs**
The American Association for the Treatment of Opioid Dependence wishes to take steps to ensure that no disabled person is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you require any auxiliary aids or services identified in the Americans with Disabilities Act, please indicate so on your registration form.

STANDARD REGISTRATION ENDS MARCH 17, 2006
**TREATING PEOPLE WITH DIGNITY: Working with Criminal Justice and Health Care Systems**  
April 22 - 26, 2006 • Hyatt Regency Atlanta • Atlanta, Georgia

Use one form for each registrant. Photocopies of the form are acceptable. Please print clearly or type or you can register on-line at [WWW.AATOD.ORG](http://WWW.AATOD.ORG) and click on the ON-LINE REGISTRATION LINK.

**CONTACT INFORMATION:** (please print)

<table>
<thead>
<tr>
<th>First (Given) Name</th>
<th>Middle Initial</th>
<th>Last (Family) Name</th>
<th>Name on badge</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Degree</th>
<th>Affiliation (Employer)</th>
<th>Position/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Business Address</th>
<th>City</th>
<th>State/Province</th>
<th>Country</th>
<th>Zip Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Business Telephone</th>
<th>Fax Number</th>
<th>E-Mail Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PLEASE CHECK ONLY THE PROFESSIONAL DESIGNATION THAT APPLIES:**

- Clinical / Medical
- Funding Evaluation
- Research
- Counseling
- Administrative / Management
- Policy
- Other (Please Specify)

**FULL CONFERENCE REGISTRATION:**
Includes Welcome Reception, Networking Reception and Awards Banquet

- Check all that apply

<table>
<thead>
<tr>
<th>Event</th>
<th>Fee enclosed</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>One person from an agency</td>
<td>$485</td>
<td>$_____</td>
</tr>
<tr>
<td>Two or more from an agency</td>
<td>$450</td>
<td>$_____</td>
</tr>
<tr>
<td>Single Day (specify day below)</td>
<td>$215</td>
<td>$_____</td>
</tr>
<tr>
<td>Sunday</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday (Does not include Awards Banquet)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Yes, I will be attending the Welcome Reception
- No, I will not attend the Welcome Reception
- Yes, I will be attending the Awards Banquet
- No, I will not attend the Awards Banquet

- Clinicians Course $150 $_____

**CME/CEU FEES (NOT INCLUDED IN CONFERENCE REGISTRATION FEE)**

- Physicians $40 $_____
- Physician Assistants $30 $_____
- Pharmacists $40 $_____
- Nurses $30 $_____
- Social Workers $20 $_____
- Psychologists $30 $_____
- Counselors $20 $_____

**PAYMENT INFORMATION:**

- I wish to pay my fees by CHECK

  (made payable to the American Association for the Treatment of Opioid Dependence)

  To assure prompt processing of your registration, please be sure to remit your check in U.S. dollars and issued by a U.S. correspondent bank. Please check with your local bank before processing payment. Each registrant is responsible for any and all bank charges. A $50.00 processing fee will be charged for checks returned unpaid.

- I wish to pay my fees by CREDIT CARD

  Please note this charge will appear on your statement as
  *AATOD Conference Registration*

<table>
<thead>
<tr>
<th>Credit Card Type</th>
<th>Digits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visa</td>
<td>13-16</td>
</tr>
<tr>
<td>MasterCard</td>
<td>16</td>
</tr>
<tr>
<td>American Express</td>
<td>15</td>
</tr>
</tbody>
</table>

**TOTAL FEES TO BE CHARGED $______**

**Please Note:**

Guest tickets for the Welcome Reception may be purchased on site for $20.00. Guest Tickets for the Awards Banquet may be purchased on site for $65.00.

Register for the conference on-line at [www.aatod.org](http://www.aatod.org) or mail or fax the Registration form with your payment in full to:

**AATOD - Conference 2006 Registration**  
13 Mantua Road  
Mt. Royal, New Jersey 08061

**CANCELLATION POLICY**

If you must cancel your registration, the American Association for the Treatment of Opioid Dependence Registration Department must receive all requests in writing no later than March 17, 2006. All fees paid will be returned less a $50.00 processing fee. **THERE WILL BE NO REFUNDS AFTER THE MARCH 17TH DEADLINE.**

**REPLACEMENT POLICY**

Replacements will only be processed when requests are received in writing prior to March 17, 2006. **There will be no replacements after that date.**

Participation in this conference assumes knowledge and authorization of audio and/or video recording of portions of this conference. Registration will be confirmed in writing within two weeks of receipt of payment. If you do not receive confirmation by that time, please call 856-423-3091.
Atlanta 2006